Reply to B. Rini et al and S. Buti et al

Toni K Choueiri¹, Susan Halabi¹, Michael J Morris¹, Daniel George¹

Affiliations

Affiliation

¹ Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Susan Halabi, Duke University, Durham, NC; Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel George, Duke University Medical Center, Durham, NC.

PMID: 28549224
DOI: 10.1200/JCO.2017.72.2629

Comment

Reply to B. Rini et al and S. Buti et al

Toni K Choueiri et al. J Clin Oncol. 2017.

. 2017 Jun 1;35(16):1859-1860.

doi: 10.1200/JCO.2017.72.2629. Epub 2017 Mar 6.

Authors

Toni K Choueiri¹, Susan Halabi¹, Michael J Morris¹, Daniel George¹

Affiliation

¹ Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Susan Halabi, Duke University, Durham, NC; Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel George, Duke University Medical Center, Durham, NC.

PMID: 28549224
DOI: 10.1200/JCO.2017.72.2629

No abstract available

PubMed Disclaimer

Comment on

Future Challenges for Drug Development in Renal Cell Carcinoma.
Rini BI, Vogelzang NJ. Rini BI, et al. J Clin Oncol. 2017 Feb 20;35(6):577-579. doi: 10.1200/JCO.2016.71.0673. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992269 No abstract available.
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Choueiri TK, et al. J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14. J Clin Oncol. 2017. PMID: 28199818 Free PMC article. Clinical Trial.
Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
Buti S, Bersanelli M. Buti S, et al. J Clin Oncol. 2017 Jun 1;35(16):1858-1859. doi: 10.1200/JCO.2016.71.6506. Epub 2017 Mar 6. J Clin Oncol. 2017. PMID: 28549228 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to B. Rini et al and S. Buti et al

Affiliation

Reply to B. Rini et al and S. Buti et al

Authors

Affiliation

Comment on

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical